In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease

Environ Sci Pollut Res Int. 2022 Apr;29(18):26775-26791. doi: 10.1007/s11356-021-17642-9. Epub 2021 Dec 2.

Abstract

Coronavirus disease 2019 (COVID-19) is a rapidly growing pandemic that requires urgent therapeutic intervention. Finding potential anti COVID-19 drugs aside from approved vaccines is progressively going on. The chemically diverse natural products represent valuable sources for drug leads. In this study, we aimed to find out safe and effective COVID-19 protease inhibitors from a library of natural products which share the main nucleus/skeleton of FDA-approved drugs that were employed in COVID-19 treatment guidelines or repurposed by previous studies. Our library was subjected to virtual screening against SARS-CoV Main protease (Mpro) using Molecular Operating Environment (MOE) software. Twenty-two out of those natural candidates showed higher binding scores compared to their analogues. We repurpose these natural products including alkaloids, glucosinolates, and phenolics as potential platforms for the development of anti-SARS-CoV-2 therapeutics. This study paves the way towards discovering a lead used in the treatment of COVID-19 from natural sources and introduces phytomedicines with dual therapeutic effects against COVID-19 besides their original pharmacological effects. We recommend further in vitro evaluation of their anti-COVID-19 activity and future clinical studies.

Keywords: Alkaloids; COVID-19; Glucosinolates; Mpro; Phytomedicines; Phytoremedies; Virtual screening.

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Biological Products*
  • COVID-19 Drug Treatment*
  • Coronavirus 3C Proteases
  • Humans
  • Molecular Docking Simulation
  • Phytochemicals / pharmacology

Substances

  • Antiviral Agents
  • Biological Products
  • Phytochemicals
  • 3C-like protease, SARS coronavirus
  • Coronavirus 3C Proteases